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In this report it is described for the first time the expression and purification of large 
quantities of a soluble and correctly folded chimeric recombinant protein, E2661E1340, 
containing the permuted Hepatitis C virus (HCV) glycoprotein ectodomains E1 
(aminoacids 192-340) and E2 (aminoacids 384-661). Using the baculovirus/insect 
cell expression system, 8 mg of secreted protein were purified from 1 L of culture 
media, a yield 4 times higher than the described for its counterpart E1341E2661. This 
permuted chimeric protein is glycosylated and possesses a high tendency to self-
associate. The fluorescence emission spectrum indicates that Trp residues occupy a 
relatively low hydrophobic environment. The secondary structure was determined by 
deconvolution of the far-UV circular dichroism spectrum yielding 13% -helix 
structure, 49% extended structure and 38% non-ordered structure. E2661E1340 binds 
to antibodies present in human sera from HCV-positive patients, a binding that is 
blocked at different levels by a rabbit anti-E2661 antibody. All these structural and 
antigenic features of E2661E1340 are very similar to those described for E1340E2661, 
Thus, this high-yield isolated chimeric protein may be a valuable tool to study the 
first steps of the HCV infection. 
 
 




 Hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis, 
and hepatocellular carcinoma worldwide (Major et al., 2001). HCV is a positive 
sense, single-stranded RNA virus belonging to the Hepacivirus genus of the 
Flaviviridae family. Currently, there is no vaccine for HCV and the antiviral therapy 
which is used include the use of polyethylene glycol-modified interferon, ribavirin 
and protease inhibitors although there are also other drugs in phase III of clinical 
development (Imran et al., 2014). Unfortunately, all the treatments are expensive and 
are not 100% effective (Feld and Hoofnagle, 2005). 
 The HCV envelope glycoproteins, E1 (gp31) and E2 (gp70), are released from 
the polyprotein coded for by the HCV genome after cleavage by host-cell 
endoplasmic reticulum proteases in positions 383/384 and 746/747 of the sequence, 
respectively (Mizushima et al., 1994). According to the amino acid sequence analysis 
of E1 and E2, these highly glycosylated glycoproteins are classified as type I integral 
transmembrane proteins with an N-terminal ectodomain (residues 192-340 and 384-
661 of the polyprotein for E1 and E2 respectively) and a C-terminal hydrophobic 
domain anchor. In vitro expression studies have shown that both glycoproteins 
associate to form a stable non-covalently linked heterodimer, which accumulate in the 
endoplasmic reticulum, the proposed site for HCV assembly and budding (Op De 
Beeck et al., 2001). On the other hand, studies carried out using cell-cultured HCV 
(HCVcc) have shown that the envelope glycoproteins E1 and E2 are able to form 
large covalent complexes stabilized by disulfide bridges in the virion (Vieyres et al., 
2010).  
 HCV envelope glycoproteins E1 and E2 play an essential role in virus entry 
into host cells by interacting with cell surface receptors, and inducing fusion between 
4 
 
the viral and cellular membranes (Nielsen et al., 2004; Bartosch et al., 2003). E2 is 
the primary glycoprotein responsible for the interaction with cellular receptors 
including heparan sulfate, the tetraspanin CD81, the scavenger receptor BI, the tight 
junction proteins claudin-1 and occludin, the Niemann-Pic C1-like 1 cholesterol 
absorption receptor and other factors (reviewed in (Ploss and Dubuisson, 2012), 
while little is known about the exact role of E1 protein. It has been shown that E1 
folding (either the ectodomain or the full length protein) is dependent on E2 co-
expression (Sandrin et al., 2005; Patel et al., 2001; Michalak et al., 1997), and that 
full-length E2 folding is also dependent on E1 co-expression (Brazzoli et al., 2005; 
Cocquerel et al., 2001). These observations indicate that HCV envelope glycoproteins 
cooperate to form a functional complex.  
 The difficulty of propagating HCV in cell culture has hampered for many years 
functional studies on HCV infection. The cellular mechanism of HCV entry has been 
studied using HCV pseudoparticles (HCVpp), infectious retroviral particles with HCV 
envelope proteins on the surface, and the cell culture model which allows for the 
production and propagation of virus in cell culture (HCVcc) (Lindenbach and Rice, 
2005; Wakita et al., 2005; Zhong et al., 2005). Despite that E1 and E2 have been 
expressed in several prokaryotic (Hüssy et al., 1997) or eukaryotic (Lorent et al., 2008; 
Mustilli et al., 1999; Michalak et al., 1997; Hüssy et al., 1996) cell lines, few data 
concerning to the structure of isolated proteins have been obtained. Most of the 
structural studies have been focused on the E2 protein, since, contrary to the full-length 
polypeptide, the E2 ectodomain has been characterized as an independent folding unit 
(Rodriguez-Rodriguez et al., 2009; Whidby et al., 2009). Thus, very recently, two 
different groups have described the crystal structure of the E2 core ectodomain in 
complex with antibodies (Khan et al., 2014; Kong et al., 2013). 
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However, attempts to analyse the structure of the E1 ectodomain have been 
hindered by the impossibility to isolate this protein in a native-like conformation, 
probably due to the above mentioned folding dependency on E2. In order to 
overcome this problem, a recombinant chimeric protein containing both E1 and E2 
ectodomains connected by a small hydrophilic peptide, E1341E2661, has been 
previously shown to have all the features of a correctly folded polypeptide (Tello et 
al., 2010).  In this work, the cloning, expression and purification of a new chimeric 
protein based on permuted E1 and E2 ectodomains in a baculovirus/insect cell system 
is described. Also, the characterization of some structural and functional properties is 
presented. This chimera was produced with a yield four times that described for 
E1341E2661. Several criteria indicate that E2661E1340 is correctly folded and processed. 
Moreover, different biochemical, spectroscopic and antigenic studies indicated that 






2. Materials and methods 
 
2.1. Plasmids constructions 
The E1 and E2 DNA encoding sequences were obtained by RT-PCR from the 
viral RNA of a HCV1 strain, genotype 1a (Accession number M62321). In order to 
connect E2 and E1 ectodomains by a flexible, protease susceptible peptide, the E1 
gene was subcloned into the pProEx-HTb vector (Life Technologies, Grand Island, 
NY, USA), which contains the sequence encoding the TEV protease recognition site 
upstream of the cloning site. For this subcloning, E1 gene was amplified by PCR 
using the pAcGP67A-E1340-E2661 (Tello et al., 2010) vector as template and the 
primers cg cc atg gaa ttc atg TAC CAA GTG CGC AAC (forward, Nco I restriction 
site underlined) and ca gcggccgc tca GAT CCG GAG CAG CTG (reverse, Not I site 
underlined). The resulting plasmid, pPROEX-E1340 was used as template for a second 
PCR reaction using the same E1 reverse primer and the following forward primer:   
ga aga tct gat tac gat atc cca cg, thus obtaining a fragment containing spacer-TEV 
protease sequence preceeding E1, as well as a Bgl II restriction site (underlined). 
Finally, after  a three fragment ligation between a) pAcGP67A-E2661 (Rodriguez-
Rodriguez et al., 2009) digested with Nhe I/Not I (contains E2384-438), b) the fragment 
E2438-661, obtained after digestion of   pAcGP67A-E1340-E2661 with Nhe I/Bgl II, and 
c) spacer-TEV-E1 digested with Bgl II/Not I, the recombinant plasmid pAcG-
E2661E1340 was obtained. 
 
2.2. Insect cell culture and transfections 
 After the culture of insect cell line Spodoptera frugiperda (Sf9) in Insect X-
Press serum-free media (BioWhittaker, Lonza, Walkersville, MD, USA) at 27 ºC, Sf9 
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cells were cotransfected with BaculogoldTM DNA (BD Biosciences, San Jose, CA, 
USA) and the recombinant transfer vector pAcGP67A- E2661E1340 as indicated by the 
manufacturer. BaculogoldTM DNA is a modified wild baculovirus DNA which 
contains a lethal deletion and cannot develop into a viable virus by itself. 
Recombination between the flanking regions of the polyhedrin gene from the transfer 
vector and modified wild-type baculovirus DNA therefore results in 100% 
recombinant baculovirus DNA. After several rounds of culture amplifiyng the 
recombinant virus, a high titer virus stock solution was harvested. On a larger scale 
protein expression, High FiveTM insect cells (Invitrogen, Carlsbad, CA, USA) were 
grown in Insect X-Press serum-free media prior to infection with high titer virus 
(>108 pfu/ml) at a multiplicity of infection of  5-10. 
 
2.3. Purification of E2661E1340 
  500 ml of recombinant baculovirus-infected insect cell cultures were 
harvested approximately 120 h postinfection and the cells pelleted by centrifugation 
at 5000 g for 10 min. The supernatant was dialyzed against 20 mM Tris-HCl pH 7.0, 
50 mM NaCl and loaded onto a Ni2+-Nitrilotriacetic acid agarose (Ni-NTA-agarose) 
column (Qiagen, Hilden, Germany) which had been previously equilibrated with the 
same buffer at a flow rate of 0.5 ml/min. About 3 ml of gel were used per liter of 
culture supernatant. Once the protein solution had entered the column, it was washed 
with dialysis buffer containing 10 mM imidazole and later 30 mM imidazole. The 
recombinant E2661E1340 protein was eluted with 200 mM imidazole in dialysis buffer. 





2.4. Protein analysis 
Protein concentration was determined by using the absorbance at 280 nm and 
the extinction coefficient calculated from the amino acid analysis. The absorption 
spectra were recorded on a Beckman DU-640 spectrophotometer (Beckman Coulter, 
Brea, CA, USA). The amino acid analysis of hydrolyzed aliquots was performed on a 
Beckman 6300 automatic analyzer (Beckman Coulter, Brea, CA, USA). 
Approximately, 20 g of purified protein were hydrolyzed with 5.9 N tridistilled HCl 
at 110 ºC for 24 h. Norleucine was used as an internal standard. Automated Edman 
protein degradation of E2661E1340 was performed using an Applied Biosystems 494 
gas-phase sequencer (Life Technologies, Grand Island, NY, USA). 
 
2.5. Protein Deglycosylation 
  Digestion of protein samples with N-glycosidase F (PNGase F, Roche 
Diagnostics, Mannheim, Germany) was carried out for 16 h at 37 ºC in 20 mM 
sodium phosphate pH 7.0, 50 mM EDTA, and 1% (p/v) octylglucoside. Then, 
digested samples were mixed with 3X Laemmli sample buffer, analyzed by SDS-
PAGE and stained with Coomassie brilliant blue R 250. The proteins were also 
transferred to nitrocellulose membranes that were subsequently incubated with the 
lectin concanavalin A conjugated to biotin (Pierce, Rockford, IL, USA). The 
glycoproteins were detected using HRP-streptavidin at a 1:1000 dilution. 
 
2.6. Circular Dichroism 
  CD spectra were recorded with a Jasco spectropolarimeter, model J-715 
(Jasco, Easton, MD, USA) at 25 ºC with cells thermostated with a Neslab RTE-111 
water bath. Far-UV CD spectra were measured at a protein concentration of 0.15 
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mg/ml in 20 mM Tris-HCl pH 7, 50 mM NaCl. The pathlength was 1mm. Five scans 
were averaged for each measurements and the contribution of the buffer was always 
subtracted. The spectra were calculated by using 110 as the mean residue molecular 
mass and the results are expressed in terms of residue molar ellipticity in 
degcm2dmol-1. The secondary structure of the protein was evaluated by computer fit 
of the dichroism spectra according to Convex Constraint Analysis (CCA) (Perczel et 
al., 1991). This method relies on an algorithm that calculates the contribution of the 
secondary structure elements that give rise to the original spectral curve without 
referring to spectra from model systems. The secondary structure was also predicted 
by the GOR IV method (Garnier et al., 1996).  
 
2.7. Fluorescence spectroscopy 
  Emission spectra were obtained at 25 ºC using an SLM AMINCO 8000C  
spectrofluorimeter (SLM Instruments, Urbana, IL, USA), fitted with a 450-W xenon 
arc. Excitation and emission slit widths were set at 4 nm. The protein concentration 
was 0.05 mg/ml and a 0.4 x 1 cm cuvette was used. Buffer was 20 mM Tris-HCl pH 
7, 50 mM NaCl. Excitation was performed at 275 or 295 nm, and the emission 
spectra were recorded over the range 285-450 nm. The contribution of the buffer was 
always subtracted. The tyrosine contribution to the emission spectra was calculated 
by subtracting the emission spectrum measured at exc = 295 nm multiplied by a 
factor from that measured at exc = 275 nm. The factor was obtained from the ratio 
between the fluorescence intensities measured with exc = 275 and exc = 295 nm at 





 2.8. SDS-PAGE 
  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed according to Laemmli using 15% polyacrylamide gels (Laemmli, 1970). 
Samples were subjected to gel electrophoresis under either nonreducing or reducing 
conditions (with 5% (v/v) -mercaptoethanol) and the proteins were stained with 
Coomassie brilliant blue R-250. The molecular mass of the protein bands was 
estimated by comparison with protein markers of known molecular mass (Prestained 
SDS-PAGE Standards, Bio-Rad, Hercules, CA, USA). 
 
2.9. Western blotting 
After SDS-PAGE, proteins were transferred to nitrocellulose membranes 
(Hybond-ECL; Amersham, Piscataway, NJ, USA) in 48 mM Tris-HCl pH 9.0, 
containing 39 mM glycine, 0.0375% SDS and 20% (v/v) methanol, for 1 h at 1 
mA/cm2, by using a V20-SDB apparatus (Scie-Plas, Cambridge, UK). To detect 
E2661E1340, membranes were incubated with a HRP-conjugated monoclonal anti-His 
(Sigma-Aldrich, St. Louis, MO, USA) at a 1:3000 dilution. The peroxidase reaction 
was developed with 3,3’-diaminobenzidine tetrahydrochloride/H2O2. For 
recombinant protein detection with the mouse anti-E1 (Acris Antibodies, Herford, 
Germany) and rabbit anti-E2661 antibodies, nitrocellulose membrane was incubated 
with these antibodies at 1:1000 dilution with 0.1% Tween 20 in PBS. Following 
overnight incubation, the membrane was washed extensively with PBS containing 
0.1% Tween 20. After that, membrane was incubated with a goat anti-mouse or goat 
anti-rabbit antibodies in each case at 1:3000 dilution for 2 hours. After membrane 
washing, the immunoblots were developed as described above.  
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Polyclonal antibody against recombinant protein, E2661 (Rodriguez-Rodriguez 
et al., 2009), was prepared by immunizing New Zeeland white rabbits over a 6-week 
period by weekly injection of the protein (100 μg) in complete Freund´s adjuvant. 
 
2.10. Enzyme Linked Immunosorbent Assay (ELISA) 
96 wells microtitre plates (Corning, Tewksbury, MA, USA)were coated 
overnight at 4 ºC with 100 ng/well of purified recombinant E2661E1340 or E1341E2661 
diluted to 1 g/ml in 0.05 M carbonate-bicarbonate buffer, pH 9.6. Unbound antigen 
was discarded, and the wells were blocked with 3% non-fat dry milk in PBS for 60 
min at room temperature. After washing the wells were incubated at 37ºC for 2 h with 
human serum. Eight HCV-positive human sera and ten HCV-negative human sera 
were used at a dilution of 1:200. The plates were washed three times with PBS/0.05% 
Tween 20 and incubated at 37 ºC for 1 h with HRP-conjugated anti-human IgG (Fc) 
diluted at 1:10000. Bound antibodies were detected by adding 100 mM sodium 
citrate, pH 5.0, 4% Methanol buffer containing H2O2 and the substrate o-
phenylenediamine dihydrochloride (Merck, Whitehouse Station, NJ, USA). The 
optical density at 492 nm was measured using an ELISA Expert 96 microplate reader 
(ASYS Hitech, Cambridge, UK). Sera from infected and control patients were 
provided by Dr. Fernando Vivanco (Fundación Jiménez Díaz, Madrid, Spain). ELISA 
inhibition assays were performed as described (Cocquerel et al., 2001). After coating 
with 100 μl of antigen (1g/mL), the plates were incubated with HCV infected 
patients sera (diluted 1:20) previously mixed with a 10-1 dilution of the inhibitor 
(rabbit anti-E2661 serum). Binding of human IgG was detected as described above. 





 E2661E1340 was immunoprecipitated with H53 monoclonal antibody following 
the procedure previously used for E1341E2661 (Tello et al., 2010). The MAb H53 is 






3.1. Expression and purification of E2661E1340 
 
The recombinant E2661E1340 protein has 457 amino acids, 149 corresponding 
to positions 192-340 of E1, 278 corresponding to positions 384-661 of E2 and the 
rest being due to the cloning strategy, to the spacer-TEV sequence between E1 and 
E2, and to the amino-terminal His tag used to purify the protein (Fig. 1a).  
The chimeric protein was expressed in High FiveTM insect cells transfected 
with the pAcGP67A-E2661E1340 plasmid along with wild-type viral DNA. In a 
homologous recombination event, the E2661E1340 gene was inserted into the viral 
genome. The protein was expressed by infecting a new batch of insect cells using 
amplified recombinant virus. Cells were grown and protocols were carried out as 
described in Materials and methods. As described for E1341E2661 (Tello et al., 2010), 
the protein was expressed in a soluble form and secreted to the extracellular medium. 
However, the amount of the secreted E2E1 chimera was significantly higher than the 
observed for the E1E2 polypeptide when they were followed in an interval of 2-5 
days of infection (Fig. 1b). 
E2661E1340 secreted to the extracellular media was subsequently purified using 
affinity chromatography on a Ni-nitriliotriacetic acid-agarose column (Fig. 1c). The 
protein that elutes with 200 mM imidazole was determined to be > 95% pure by 
densitometry of stained SDS gels. Furthermore, the purified protein was recognized 
by the monoclonal anti-His6 and anti-E1 antibodies and the polyclonal anti-E2661 
antibody (Fig. 1c). Following this procedure, approximately 7-8 mg of E2661E1340 
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protein were obtained from 1 L of culture media. This value represents 4-fold the 
yield obtained for E1341E2661 (2 mg per liter) (Tello et al., 2010). 
 
3.2. Biochemical characterization of E2661E1340 
 
The amino acid composition of the recombinant secreted protein determined 
by aminoacid analysis was identical to that deduced from the cDNA sequence (data 
not shown). A value of 1.98 for E0.1% at 280 nm was experimentally calculated. 
Moreover, the first six Edman degradation steps of E2661E1340 were identical to the 
theoretical sequence: ADPHHH. Then, the signal peptide gp67 has been correctly 
cleaved by cellular proteases, allowing the secretion of the processed protein. 
  SDS-PAGE analysis of the recombinant protein in the presence of reducing 
agents showed a single band with a molecular mass of 63 kDa (Fig. 2b), while the 
theoretical mass based on the amino acid sequence is 50.5 kDa. Thus, as observed for 
E1341E2661 (Tello et al., 2010), E2661E1340 seems to be also glycosylated. In fact, 
when the recombinant protein was treated with PNGase F, which releases asparagine-
linked (N-linked) oligosacharides from glycoproteins, the molecular mass of 
E2661E1340 decreases to 53 kDa (Fig. 2a). Nevertheless, carbohydrates were still 
detected with concanavaline A in treated recombinant protein with PNGase F (Fig. 
2a), indicating that E2661E1340 must contain N-glycosidic bonds which are not 
accessible to PNGase F or the presence of O-glycosidic bonds.   
SDS-PAGE in the absence of reducing agents showed four main bands which 
have molecular masses that could correspond to monomeric, dimeric, trimeric and 
tetrameric forms of E2661E1340 (Fig. 2b). Also, higher order structures which do not 
enter the gel were observed. However, when the gel was run in the presence of 
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reducing agents only one band was observed that could correspond to the monomer 
(Fig. 2b). Therefore, E2661E1340 would self-associate at least through disulfide 
bridges. The same pattern of oligomerization was observed with the recombinant 
E1E2 glycoprotein (Tello et al., 2010). 
 
3.3. Spectroscopic analysis of E2661E1340 
 
The spectroscopic characterization of E2661E1340 and was carried out by 
means of circular dichroism and fluorescence spectroscopies and compared to those 
of E1341E2661. The far-UV CD spectra of both chimeric proteins were similar, 
showing a minimum at 208 nm (Fig. 3). Deconvolution of these spectra using the 
program Convex Constraint Analysis (CCA) (Perczel et al., 1991) indicated that both 
chimeric proteins have almost identical secondary structure (Table 1), with a high 
content in non-ordered structure (38-39%), being the β-sheet the main ordered 
structure (Table 1). The predictive GOR IV method (Garnier et al., 1996), which is 
based upon the propensity of each amino acid to adopt a particular secondary 
structure, yielded a secondary structure for E2661E1340 and E1341E2661which is not too 
different from the experimental one.  
The fluorescence emission spectra of E2661E1340 and E1341E2661 were identical 
(Fig. 4). Upon excitation at 275 nm, the recombinant proteins exhibited a maximum 
at 331 nm, indicating that the fluorescence of these proteins is highly dominated by 
tryptophan residues and that they occupy a relatively hydrophobic environment. 
Upon excitation at 295 nm, the position of the fluorescence emission maximum was 
around 330 nm for both proteins (data not shown). 
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The difference between the fluorescence spectra obtained upon excitation at 
275 and 295 nm, the latter being normalized, indicates that the contribution of 
tyrosine residues to the recombinant protein fluorescence was very low, 
approximately 5 %, upon excitation at 275 nm (Fig. 4). 
 
3.4. Antigenic characterization of E2661E1340 and E1341E2661 
 
In order to assess the antigenic properties of E2661E1340, and compare to those 
of E1341E2661, a panel of eight HCV-positive and ten HCV-negative human sera were 
used in ELISA. Fig. 5 shows the results obtained for both proteins in assays 
performed at the same time and in the same conditions. The values of absorbance at 
492 nm for all ten HCV-negative sera were almost negligible (data not shown). As it 
can be observed, the A492 values are generally very similar for both proteins, although 
a significant increase in the binding of IgGs present in sera 2, 3 and 6 to E2661E1340 is 
detected. Nevertheless, these results suggest that the epitopes expressed in the surface 
of both proteins must be very similar. 
On the other hand, Fig. 6 shows the results of an experiment of inhibition of 
the binding of both recombinant proteins to the antibodies present in the same eight 
HCV-positive, exerted by a polyclonal anti-E2661 antibody. The inhibition 
experiments using the sera were carried out using a 10-1 dilution of the anti-E2661 
antibody. At this dilution, inhibition studies showed that the polyclonal anti-E2661 
antibody blocked the binding of the IgGs from the eight HCV-positive sera at 
different levels. Thus, for sera 5 and 6, the binding of IgG to E1341E2661 and 
E2661E1340 was strongly inhibited by the anti-E2661 antibody; in the cases of sera 3 
and 7 significant difference were observed  between both chimeras, with inverted 
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inhibition percentages, higher in serum 3 for E2661E1340, and higher in serum 7 for 
E1341E2661. These differences can be attributed to local variations in the exposure of 
some E2 epitopes in both chimeric proteins. However, in general the averages of 
inhibition, 62% for E2E1 and 69% for E1E2, were once again very similar. 
The conformation of the E2 moiety of the chimera was assessed with the 
monoclonal antibody H53 which is conformation-dependent. The chimeric protein 
was efficiently immunoprecipitated by the antibody indicating the native-like 







The HCV envelope glycoproteins, E1 and E2, are the essential players for 
binding and entry of the virus into the cells. Consequently, they are the main focus of 
neutralizing antibodies and, hence, have become important targets for vaccine 
design. Leaving aside the importance of the transmembrane C-terminal regions of 
both proteins, it seems evident that recombinant glycoprotein E1 and E2 ectodomains 
can be a valuable tool to study the structure-function relationship of these 
polypeptides. In this regard, it has been described that the folding of the E2 
ectodomain is independent of E1, but truncated E2 is required for the proper folding 
of E1 ectodomain ( Patel et al., 2001; Michalak et al., 1997). Hence, isolated 
properly folded E2 ectodomain produced either using the baculovirus-insect cell 
system (Rodriguez-Rodriguez et al., 2009) or using human HEK293 cells (Whidby et 
al., 2009) has been characterized and, very recently, the detailed structure of this 
truncated form bound to an antigen binding fragment has been described (Khan et al., 
2014; Kong et al., 2013). Conversely, to date, no structural data of an isolated, 
properly folded, E1 ectodomain appears in the bibliography. In order to circumvent 
the problem, an alternative strategy has been to design a tandem chimeric 
polypeptide based on both E1 and E2 ectodomains. In a first attempt, a bacterially 
expressed chimeric protein E1E2, purified in presence of 6 M Urea, was maintained 
soluble only after dialysis in the presence of both 0.1% Triton X-100 and 0.2% BSA, 
which precludes any subsequent structural study (Xiang et al., 2006). However, using 
the baculovirus system, the expression, secretion and purification in native 
conditions of the chimeric recombinant protein E1341E2661, containing the E1 and the 
E2 ectodomains linked by a hydrophilic and flexible FLAG sequence has been 
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previously achieved (Tello et al., 2010). Biochemical, spectroscopical and antigenic 
characterization of this isolated chimeric polypeptide indicated that E1341E2661 
behaved as a properly folded glycoprotein. Moreover, this chimera has been recently 
used as a tool to study the fusogenic properties of the HCV envelope proteins (Tello 
et al., 2014). In this report, a novel recombinant chimeric polypeptide, E2661E1340, 
has been produced. with both enveloped proteins permuted, and compared its 
properties with the described E1341E2661. Using the same baculovirus/insect cell 
system, E2661E1340 was secreted and purified with a yield, (8 mg per liter of culure 
media) similar to that described for the E2 ectodomain alone (Rodriguez-Rodriguez 
et al., 2009) which is at least four times the yield obtained for E1341E2661 (up to 2 
mg/L of culture). This considerable increase in the secretion of the processed protein 
when the E2 ectodomain is located in the amino terminal region of the chimeric 
polypeptide is another proof of the relevant role of the E2 ectodomain as a chaperone 
for the folding of E1. 
Both chimeras contain the same E1 and E2 ectodomain sequences, but differ 
in the composition of the connecting hydrophilic peptide. The FLAG-enterokinase 
linker contained in E1341E2661 was substituted in E2661E1340 by a spacer-TEV 
protease recognition sequence with the aim to facilitate obtaining both domains in a 
separate and soluble form. This would be particularly interesting in the case of E1, 
since, as mentioned above, it has never been isolated in a native conformation. 
However, as occurred for E1341E2661 after treatment with enterokinase, all attempts to 
cleave the TEV-cleavage site failed (data not shown) indicating the intricate 
interaction between both ectodomains. 
Despite the difference between the linker region both E1341E2661 and 
E2661E1340, chimeric glycoproteins show very similar conformations. Thus, the 
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circular dichroism far-UV spectrum showed that the recombinant proteins E1341E2661 
and E2661E1340 share a high content of non-regular structure, with -sheet as the 
major ordered secondary structure element. The -helix structure is present in a 
rather low percentage. This secondary structure is very similar to the recently 
described for the E2 ectodomain (Khan et al., 2014; Kong et al., 2013). On the other 
hand, the fluorescence emission maximum corresponding to the tryptophan residues 
of the proteins is centered at 331 nm, indicating that these residues are located in a 
moderately hydrophobic environment. Taken together these results indicate that 
chimeric proteins have an open conformation, but different from a denatured state.  
The results obtained in the antigenicity studies by ELISA using a panel of 
HCV-positive human sera also indicated that both E1341E2661 and E2661E1340 were 
specifically recognized by the IgGs present in these sera in a similar way. In sera 
with low ELISA signals, an increase in the binding to E2661E1340 compared to 
E1341E2661 can be detected, especially significant for sera 2, 3 and 6, indicating that 
the chimera with permuted ectodomains showed even higher ability to bind to human 
antibodies. On the other hand, 6 out of 8 sera showed almost identical percentage of 
inhibition by anti E2661 to the binding of both proteins. Thus, from the antigenic 
studies it can be concluded that the order of both E1 andE2 ectodomains in the 
polypeptide chain does not affect significantly the recognition by the antibodies 
present in the HCV-positive patient sera.  
Regarding the oligomeric state of E2E1, SDS-PAGE in the absence of 
reducing agents showed four main bands which have molecular masses that could 
correspond to monomeric, dimeric, trimeric and tetrameric forms of E2661E1340, 
being the majority corresponding to the dimeric form. These results are indicative of 
a tendency to self-associate, a behavior that has already been reported not only for 
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E1340E2661 (Tello et al., 2010), but also for the recombinant E2 ectodomain produced 
in the baculovirus/insect cell system (Rodriguez-Rodriguez et al., 2009). There is 
some controversy regarding the functionality of the HCV envelope glycoproteins and 
the formation of intermolecular covalent complexes. Although it has been described 
that the appearance of large covalent E1E2 complexes  corresponds to nonfunctional 
aggregates (Op De Beeck et al., 2004), more recent studies, using the HCVcc system 
demonstrated the selective incorporation into secreted virions of large E1E2 
disulfide-linked complexes that maintain a native conformation as they were able to 
bind conformation-sensitive neutralizing antibodies (Vieyres et al., 2010). Then, as 
for E1341E2661 and E2661, the disulfide-bridge oligomerization of E2661E1340 seems to 
be compatible with the maintenance of its native properties. Moreover, another proof 
of the correct conformation of the chimeric permuted glycoprotein is that, as 
observed for E21341E2661 it was able to bind to human hepatome Huh7 cells through 
CD81 (data not shown).  
 In conclusion, the results described in this manuscript point out that 
E2661E1340 recombinant protein is properly folded like E1341E2661 and presents 
antigenic properties similar to E1 and E2 assembled in the HCV virion. Moreover, 
the high yield of production of this chimeric polypeptide will allow us to perform 
new structural and functional studies which will help to shed light on the infective 
cycle of HCV. Also, this recombinant protein may be used in immunization 
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Fig. 1. (a) Schematic representation of the E2661E1340 construction. (b) and (c) 
Analysis of the expression of E2661E1340 by High FiveTM cells. (b) Secretion of 
E1341E2661 (○) and E2661E1340 (●) chimeras upon 2-5 days infection. The amount of 
protein was measured by densitometry of anti-His-PO western blot band intensities. 
(c) (left) SDS-PAGE of purified E2661E1340 recombinant protein. The sample was 
previously reduced with 5% (v/v) β-mercaptoethanol and boiled for 5 min. The gel 
was stained with Coomassie Brilliant blue R-250. (right) Western blot analysis of 
purified E2661E1340 using  rabbit anti-E2661, and monoclonal anti-E1and anti-His6 
antibodies.  
 
Fig. 2. Molecular characterization of E2661E1340. (a) Analysis of the deglycosylation 
of  purified E2661E1340 by PNGase F. SDS-PAGE stained with Coomassie blue and 
concanavalin A (ConA) in absence (-) and presence (+) of PNGase F. Digestion with 
PNGase F was carried out at 37 ºC for 16 h in 20 mM sodium phosphate pH 7.0, 50 
mM EDTA, and 1% (v/v) octylglucoside. (b) Oligomeric nature of E2661E1340. SDS-
PAGE of the purified E2661E1340 in presence or absence of β-mercaptoethanol. The 
positions of (a), monomer; (b), dimer; (c), trimer; (d), tetramer are marked. The gel 
was stained with Coomassie blue. 
 
Fig. 3.  Far-UV circular dichroism spectra of E2661E1340 and E1341E2661. The spectra 
were recorded in a cylindrical cuvette of 0.1 cm pathlength between 190 and 250 nm 
and the protein concentration was 0.15 mg/ml. The buffer was 20 mM Tris-HCl pH 
7, 50 mM NaCl. Both spectra were recorded five times, averaged and corrected for 
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buffer contributions. Data were collected at 25 ºC and are expressed as residue molar 
ellipticity. 
 
Fig. 4.  Fluorescence emission spectra of E2661E1340 and E1341E2661. The excitation 
wavelength was 275 nm (E2661E1340, open circles; E1341E2661, black circles). The 
emission spectra were recorded between 300 and 450 nm. The contribution of Tyr 
residues (E2661E1340, open triangles; E1341E2661, black triangles) to the emission 
spectrum was calculated as described in the Materials and methods section. Protein 
concentration was 0.05 mg/ml. The buffer was 20 mM Tris-HCL pH 7, 50 mM 
NaCl. Spectra were collected at 25 ºC. The contribution of the buffer was always 
subtracted. 
 
Fig. 5.  ELISA with HCV-positive human sera. Microtitre wells were coated 
overnight at 4 ºC with E2661E1340 or E1341E2661 recombinant proteins at 100 ng/well. 
Eight HCV-positive human sera were used at a dilution of 1:20. Bound antibodies 
were detected with peroxidase conjugated anti-human IgG (Fc) diluted at 1:10000 as 
described in the Materials and methods section. The results shown are the means ± 
standard deviations of three different experiments. 
 
Fig. 6.  Inhibition studies of the binding of E2661E1340 and E1341E2661 to HCV-
positive sera. A polyclonal rabbit anti-E2661 antibody at 10-1 dilution was used to 
block the binding of the chimeric proteins to IgGs from 8 HCV-positive sera. The 








Table 1.  
Secondary structure of E2661E1340 and E1341E2661. 
  
aThe 
experimental values  were calculated from the far-UV CD spectrum by using the deconvolution 
program CCA (Perczel et al., 1991). 





   % Experimental
a Theoreticalb 
E1341E2661 E2661E1340 E1341E2661 E2661E1340 
-helix 13 13 7 8 
-sheet 48 49 32 32 
non-ordered 39 38 61 60 
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